HENGRUI PHARMA(01276.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at CNY 2.28 billion, YoY increase of 21.78%
NewTimeSpace News: April 22, 2026, HENGRUI PHARMA(01276.HK) released its Q1 Report for the period ended December 31, 2026, Total Revenue stood at CNY 8.14 billion, increased by 12.98% YoY; Net Profit stood at CNY 2.28 billion, YoY increase of 21.56%; Profit Attributable to Shareholders stood at CNY 2.28 billion, YoY increase of 21.78%; Basic Earnings Per Share (EPS) stood at CNY 0.34.
By the close of trading on April 22, 2026, HENGRUI PHARMA(01276) saw a loss of 0.07% in its share price, closing at HKD 66.85. The full-day turnover stood at HKD 96.54 million, with the latest market capitalization at HKD 17.26 billion.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- HENGRUI PHARMA (01276.HK): Clinical trials approved for HRS-6209 capsules and HRS-4508 tablets in advanced breast cancer and solid tumors
- HENGRUI PHARMA (01276.HK): HRS-1597 tablets approved for clinical trial for weight management
- HENGRUI PHARMA (01276.HK): SHR-1179 injection approved for clinical trial, targeting weight management indication
- HENGRUI PHARMA (01276.HK): NMPA approves oteseconazole capsules for marketing in China for severe vulvovaginal candidiasis
- HENGRUI PHARMA (01276.HK): NMPA accepts marketing application for atopic dermatitis antibody Zhuotuoqibai injection
